Healthcare Private Placement and M&A Transactions Review Week Ending September 1, 2024

Navigator Medicines: The company raised $100 million of Series A venture funding in a deal led by RA Capital Management and Forbion on August 27, 2024, putting the company’s pre-money valuation at $54 million. The company is a developer of autoimmune disease treatments intended to advance biologics for targeted immune regulation and restoration.

Circle Pharma: The company closed $90 million of Series D venture funding in a deal led by The Column Group on August 29, 2024. Nextech Invest and Euclidean Capital also participated in the round. The company is a developer of a new generation of macrocycle therapies that are cell-permeable and can be delivered by multiple routes, including oral administration.

Cumulus Oncology: The company is in the process of raising $50 million of venture funding from undisclosed investors on August 29, 2024. The company is a developer of novel oncology therapies.

OrsoBio: The company raised $40 million of venture funding from undisclosed investors on August 28, 2024. The company is an operator of a clinical-stage biopharmaceutical company intended to develop therapies for organ dysfunction.

Psyomics: The company closed on GBP 30 million of an undisclosed targeted amount of Series A venture funding on August 28, 2024. The company is a developer of web-based assessment triage designed for diagnostic and pathway prediction for mental health conditions.

PrognomIQ: The company raised $34.3 million of venture funding from undisclosed investors on August 26, 2024. The company is a developer of medical test products for the detection and treatment of cancer and other complex diseases.

Viome Life Sciences: The company raised $25.4 million of venture funding from undisclosed investors on August 27, 2024. The company is an operator of a biotechnology and healthcare business intended to prevent and reverse chronic diseases.

myBiometry: The company raised $5 million of venture funding from undisclosed investors on August 30, 2024. The company is a developer of a healthcare platform designed to monitor and manage patients with chronic disease.

Thryve: The company raised EUR 4 million of Series A venture funding in a deal led by Capricorn Partners on August 30, 2024. CARMA FUND Management, CRB Health Tech and IBB Ventures also participated in the round. The company is a developer of a data interface application that connects health-related data to smartphones, wearables and connected medical products.

Roboligent: The company raised $2 million of venture funding from undisclosed investors on August 26, 2024. The company is an operator of a robotics business intended to enhance the quality of life for people with physical challenges.

BellaLift: The company raised an undisclosed amount of venture funding from Otsuka, ONCE Ventures and RYSE Asset Management on August 28, 2024. Avestria Ventures and Bridge Point Capital also participated in the round. The company is a developer of personalized digital wellness application designed for women’s health management.

Deep Breath: The company raised an undisclosed amount of venture funding from Graduate Entrepreneur on August 29, 2024. The company is a developer of a decision support system intended for optimizing mechanical lung ventilation in the ICU.

IRUBIS: The company raised an undisclosed amount of venture funding in a deal led by BioProcess360 on August 29, 2024. Verve Ventures, High-Tech Gründerfonds, Ventura BioMed Investors, Dr. Matthias Arnold, Dr. Christoph Bremus and RoBet KG also participated in the round. The company is a developer of a bioprocess monitoring instrument for online control of bioreactors by using mid-infrared spectroscopy.

Recuro Health: The company raised an undisclosed amount of venture funding from Cure Ventures on August 27, 2024. The company is a developer of a digital health platform designed for employers, providers, and managed care organizations.

Community Oncology Revitalization Enterprise Ventures / McKesson: The company, a subsidiary of Florida Cancer Specialists & Research Institute reached a definitive agreement to be acquired by McKesson for $2.5 billion on August 26, 2024. The company is a provider of oncology services based in Florida, United States.

Oruka Therapeutics / Arca Biopharma: The company acquired Arca Biopharma through a reverse merger, resulting in the combined entity trading on the Nasdaq Stock Exchange under the ticker “ORKA” on August 29, 2024. The merger included a $275 million private placement. Oruka Therapeutics is developing novel biologics designed for chronic skin diseases such as plaque psoriasis.

Eton BioScience / Individual Investor: The company, a subsidiary of Telesis Bio was acquired by Mr. Yuan Yang for $1.5 million on August 26, 2024. The company’s services include maxi prep, gene synthesis, mutagenesis, polyclonal antibody production, fragment analysis and antibody generation as well as offering products such as biochemicals, protease and metabolism assay kits for scientists in both academia and industry.

Ansh Labs / Vion Biosciences: The company was acquired by VION Biosciences, via its financial sponsors Iron Path Capital and Harvey & Company, through an LBO on August 29, 2024 for an undisclosed amount. The company is a biotech business focused on DNA sequencing and oligo synthesis.

Bowen Therapeutics / UTime: UTime reached a definitive agreement to acquire the Bowen Therapeutics laboratory of Bowen Therapeutics for an undisclosed amount on August 28, 2024. The company is an operator of a monkeypox vaccine laboratory based in Worcester, Massachusetts.

DermTech / DERM-JES: The company was acquired by DERM-JES for an undisclosed amount on August 30, 2024. DermTech Inc is a molecular diagnostic company focused on the development of non-invasive skin genomics products.